HUTCHMED's ORPATHYS-TAGRISSO Combination Cuts Progression or Death Risk 44% in Phase III Lung Cancer Trial

• HUTCHMED's Phase III SANOVO trial showed Orpathys with Tagrisso cut progression or death risk 44% in untreated EGFR-mutated, MET-overexpressing lung cancer.
• Median progression-free survival reached 24.9 months with the combination versus 13.8 months with Tagrisso alone.
• Patients with high MET overexpression had a 55% reduction in progression or death risk versus Tagrisso alone.
• Median overall survival was 44.5 months with the combination versus 34.9 months with Tagrisso alone.
• The results support plans to submit a supplemental new drug application in China for first-line use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261026-12382759), on October 26, 2026, and is solely responsible for the information contained therein.